Foghorn Therapeutics Inc. Balance Sheet
FHTX|6 years of annual SEC 10-K data (FY2020-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
Foghorn Therapeutics Inc. had $198M in total assets with negative shareholders' equity of $46M as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $80.9M | $55.5M | $80.3M | $52.2M | $92.8M | $92.8M |
| Current Assets | $163.2M | $249.6M | $240.2M | $351.4M | $190.7M | $190.7M |
| PP&E (Net) | $1.9M | $10.0M | $13.0M | $15.3M | $19.5M | - |
| Total Assets | $198.1M | $284.0M | $285.9M | $404.9M | $255.6M | $255.6M |
| Current Liabilities | $59.7M | $67.0M | $58.4M | $55.2M | $18.8M | $18.8M |
| Total Debt | - | - | - | - | $19.7M | $19.7M |
| Shareholders' Equity | -$45.5M | -$77.2M | $112.0K | $96.9M | -$88.0M | -$88.0M |